Advicenne Reports First Half Financial Results as of June 30, 2025, and Updates on Its Activities

About this update from Advicenne Sa

[{"type":"list","items":[{"val":[{"type":"text","content":"Sibnayal® end-market sales (Europe and Middle East) up 103% to €5.5 million","length":75,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"H1 products sales and royalties totaled €3.1 million, up 20%","length":60,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Financial visibility extended to the fourth quarter of 2026 thanks to debt restructuring and a €2.6 million capital increase last July","length":134,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Favorable outlook with the continued commercial momentum of Sibnayal® in its main markets and the filing of the marketing authorization application for ATRd in the United States anticipated in the fourth quarter of 2025","length":219,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":488,"olType":false},{"type":"text","content":"PARIS, September 19, 2025--(BUSINESS WIRE)--Regulatory News:","length":60,"tagName":"p"},{"type":"text","content":"Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, today reports its 2025 first half financial results, as approved on September 19, 2025 by the Board of Directors. The first half financial report is available on the Company’s website: www.advicenne.com.","length":403,"tagName":"p"},{"type":"text","content":"Didier Laurens, Chief Executive Officer of Advicenne, commented: "The first half of the fiscal year has been marked by the commitment of all Advicenne employees in preparation for the submission of the Sibnayal® marketing authorization application in the U.S. I am particularly proud of the work accomplished, and I am confident in our ability to submit the application during Q4 2025. I also note the strong growth in Sibnayal® sales in Europe and the Middle East, with the very recent announcement of marketing authorization in Saudi Arabia under favorable economic conditions. All these factors confirm the value of Sibnayal® for patients, their families, and the medical community. The coming months will be particularly important for Advicenne in achieving our value creation objectives."","length":803,"tagName":"p"},{"type":"text","content":"Highlights of 2025 Half-year financials","leng...

More updates from Advicenne Sa